NasdaqGS:REGNBiotechs
The Bull Case For Regeneron (REGN) Could Change Following New Dupixent BP Approval In Japan - Learn Why
Regeneron Pharmaceuticals and Sanofi recently received approval from Japan’s Ministry of Health, Labour and Welfare for Dupixent to treat adults with moderate-to-severe bullous pemphigoid, backed by a pivotal LIBERTY-BP-ADEPT trial showing over four times more patients on Dupixent achieved sustained remission versus placebo through Week 36.
This decision adds a seventh Japanese indication for Dupixent and introduces the first targeted, non-immunosuppressant therapy for a rare, relapsing skin...